135995-46-9 Usage
Uses
Used in Pharmaceutical Industry:
ETHYL (5-BROMOIMIDAZO[1,2-A]PYRIDIN-2-YL)ACETATE is used as an intermediate in the synthesis of pharmaceuticals for its unique structure and reactivity, enabling the production of complex molecules with potential therapeutic applications.
Used in Agrochemical Industry:
ETHYL (5-BROMOIMIDAZO[1,2-A]PYRIDIN-2-YL)ACETATE is used as an intermediate in the synthesis of agrochemicals, contributing to the development of new compounds with agricultural applications.
Used in Organic Chemistry Research:
ETHYL (5-BROMOIMIDAZO[1,2-A]PYRIDIN-2-YL)ACETATE is used as a research compound in the field of organic chemistry, facilitating the exploration of new chemical reactions and the synthesis of novel organic compounds.
Used in the Development of New Chemical Compounds:
ETHYL (5-BROMOIMIDAZO[1,2-A]PYRIDIN-2-YL)ACETATE is utilized in the development of new chemical compounds due to its unique properties, providing a foundation for creating innovative molecules with various applications.
Check Digit Verification of cas no
The CAS Registry Mumber 135995-46-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,5,9,9 and 5 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 135995-46:
(8*1)+(7*3)+(6*5)+(5*9)+(4*9)+(3*5)+(2*4)+(1*6)=169
169 % 10 = 9
So 135995-46-9 is a valid CAS Registry Number.
135995-46-9Relevant academic research and scientific papers
Triazolopyridine and imidazopyridine compounds as well as preparation method and medical application thereof
-
Paragraph 0495-0499, (2020/07/13)
The invention relates to triazolopyridine and imidazopyridine compounds as well as a preparation method and medical application thereof. Particularly, the invention relates to a compound as shown in ageneral formula (I), a preparation method thereof and a
HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME
-
Paragraph 00236-00238, (2019/04/16)
The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to the CXCR4 pathway.
CXCR4 INHIBITORS AND USES THEREOF
-
Paragraph 00363; 00364, (2018/04/11)
The present invention provides compounds, compositions thereof, and methods of using the same.
NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
-
Page/Page column 127, (2008/06/13)
The present invention relates to novel compounds of formula (I) wherein W, n, X and W’ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors - subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
